Breast Cancer

, Volume 8, Issue 1, pp 58–62 | Cite as

5′-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent Breast Cancer

  • Kazuhiko Sato
  • Hoshio Hiraide
  • Shoetsu Tamakuma
  • Toshio Tabei
  • Masasbige Maruyama
  • Mituyuki Touma
  • Haruaki Okamura
  • Fumio Matsumoto
  • Shuichi Akao
  • Hiroshi Ishikawa
  • Yoshihiro Yagi
  • Hidetaka Mochizuki
Original Article



In trecurrent breast cancer, anthracycline-containing chemotherapy is usd to maintain quality of life. However, there are several drawbacks including theraardiotoxicity. We evaluated the efficacy and toxicity of combination chemotherapy-5-fluorouridine (5′-DFUR), medroxyprogestrone acetate (MPA) and mitoxantrone hydrochloride (MIT)


Sixteanced or recurrent breast cancer were enrolled. Chemotherapy was gle, starting with MIT 10 mg/m2 intravenously on day 1, then oral 5′-DFUR 800 mg anTwo or more cycles were given


Fifteessable for response and toxicity. Thirteen patients had been treated previcycline containing regimen and 2 with CMF. There were 2 partial response patiemplete response patient (6.7%). There were 11 patients showing no change (NC) was a minor responder and 7 with a long period of NC. There was only one wase patient. The overall response rate was 20.0%. Adverse events occurred in 5 patsuppression was the most common with 5 patients becoming leukopenic (33.3was the second most common side effect, affecting 2 patients (13.3%)


Givennd preservation of QOL, the combination of MIT, 5-DFUR and MPA cine therapy for advanced or recurrent breast cancer, especially for anthra-cycline-resistant cases.

Key words

Advanced or recurrent cancer Combination therapy Anthracycline failure Quality of life 



Cyclophosphamide, adriamycin and 5-fluorouracil




Quality of life




Medroxyprogesterone acetate


Mitoxantrone hydrochloride


Complete response


No change


Minor response


Progressive disease


Cyclophosphamide, methotrexate and 5-fluorouracil


Granulocyte-stimulating factor




Cyclophosphamide and adriamycin


Pyrimidine nucleoside phosphorylase






Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed, J B Lippincott Co, Philadelphia, pp1264–332, 1993.Google Scholar
  2. 2).
    Early Breast Cancer Trialist’s Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy.Lancet 339:71–85, 1992.Google Scholar
  3. 3).
    Taguchi T: Chemotherapy for recurrent breast carcinoma.Jpn J Cancer Chemother 12:439–447, 1985.Google Scholar
  4. 4).
    Cook AF, Holman MJ, Kramer MJ,et al: Fluorinated pyrimidine nucleoside 3, Synthesis and anti-tumor activity of a series of 5′-deoxy-5-fluoropyrimidines.J Med Chem 22:1330–1335, 1979.PubMedCrossRefGoogle Scholar
  5. 5).
    Ishizuka H, Miwa M, Takemoto K,et al: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine.Gann 71:112–123, 1980 (in Japanese with English abstract).Google Scholar
  6. 6).
    Niitani H, Kimura K, Saito T,et al: Phase II study of 5′- deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer.Jpn J Cancer Chemother 12:2044–2051, 1985.Google Scholar
  7. 7).
    Koyama H, Nishizawa S, Noguchi S,et al: A combina- tion therapy with 5′-DFUR and MPA as a second line treatment for advanced/recurrent breast cancer.J Jpn Soc Cancer Ther 25:655–661, 1990.Google Scholar
  8. 8).
    Smith IE: Mitoxantrone (Novantrone): A review of experimental and early clinical studies.Cancer Treat Rev 10:103–115, 1983.PubMedCrossRefGoogle Scholar
  9. 9).
    Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. 12th ed, Kanehara Shuppan, Tokyo, pp58–68, 1996.Google Scholar
  10. 10).
    Fume H, Hara Y, Imai Y,et al: II. Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy.J Jpn Soc Cancer Ther 28:119–130, 1993.Google Scholar
  11. 11).
    Yayoi E, Takatsuka Y, Maeura Y,et al: Comparison of response to 5′-deoxy-5-fluoropyrimidine therapy alone in combination with tamoxifen or medroxypro- gesterone acetate in advanced and recurrent breast cancer.Int J Oncology 5:27–32, 1994.Google Scholar
  12. 12).
    Uchino J, Hata O, Sasaki F,et al: Comparative study of treatment using only 5′-DFUR vs combinated treatment of 5′-DFUR and MPA for advanced or recurrent breast cancer.KARKINOS 4:1295–1300, 1991.Google Scholar
  13. 13).
    Toi M, Taguchi T, Tominaga T,et al: The effect of combination treatment consisted of 5′-deoxy-5-fluo- ropyrimidine and medroxyprogesterone acetate for recurrent breast cancer patients.Jpn J Cancer Chemother 22:799–844, 1995.Google Scholar
  14. 14).
    Kusama M, Kimura K, Koyanagi Y,et al: Effects of 5′- DFUR plus Medroxyprogesterone (MPA) in breast cancer patients with bone metastasis.J Jpn Soc Cancer Ther 28:1334, 1993Google Scholar
  15. 15).
    Cornbleet MA, Stuart-Harris RC, Smith IE,et al: Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients.Eur J Cancer Clin Oncol 20:1141–1146, 1984.PubMedCrossRefGoogle Scholar
  16. 16).
    Marsoni S, Wittes R: Clinical development of anticancer agents: A National Cancer Institute Perspective.Cancer Treat Rep 68:77–85, 1984.PubMedGoogle Scholar
  17. 17).
    lino Y, Yokoe T, Sugamata N,et al: A combination chemoendocrine therapy of mitoxantrone, doxifluri- dine, and medroxyprogesterone acetate for anthracy- cline-resistant advanced breast cancer.Cancer Chemother Pharmacol 41:243–247, 1998.Google Scholar
  18. 18).
    Howell A, Mackintosh J, Jones M,et al: The defini- tion of the ‘No Change’ category in patinents treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.Eur J Cancer Clin Oncol 24:1567–1572, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2001

Authors and Affiliations

  • Kazuhiko Sato
    • 1
  • Hoshio Hiraide
    • 2
  • Shoetsu Tamakuma
    • 1
  • Toshio Tabei
    • 3
  • Masasbige Maruyama
    • 4
  • Mituyuki Touma
    • 5
  • Haruaki Okamura
    • 6
  • Fumio Matsumoto
    • 7
  • Shuichi Akao
    • 8
  • Hiroshi Ishikawa
    • 9
  • Yoshihiro Yagi
    • 9
  • Hidetaka Mochizuki
    • 1
  1. 1.Department of Surgery INational Defense Medical CollegeJapan
  2. 2.Research InstituteNational Defense Medical CollegeJapan
  3. 3.Department of SurgerySaitama Cancer CenterJapan
  4. 4.Department of SurgeryMaruyama Memorial General HospitalJapan
  5. 5.5Department of SurgeryTouma HospitalJapan
  6. 6.Department of SurgeryKasukabe City HospitalJapan
  7. 7.Department of SurgeryKoshigaya City HospitalJapan
  8. 8.Department of SurgeryKoshigaya Hospital, Dokkyo Medical CollegeJapan
  9. 9.Department of SurgeryUrayasu Ichikawa City HospitalJapan

Personalised recommendations